Crossmark

Targeting natural killer cells in cancer immunotherapy

Crossref DOI link: https://doi.org/10.1038/ni.3518

Published Online: 2016-08-19

Published Print: 2016-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guillerey, Camille

Huntington, Nicholas D http://orcid.org/0000-0002-5267-7211
Smyth, Mark J
License Information

Text and Data Mining valid from 2016-08-19
More Information

Article History

Received: 1 May 2016

Accepted: 22 June 2016

First Online: 19 August 2016

Competing interests

: M.J.S. has research agreements with Medimmune and Bristol Myers Squibb.